Inclusion Criteria:

          1. Males or females of 18 years of age or older

          2. Have histologically-proven measurable, or evaluable advanced (systemically or locally
             progressive), or metastatic solid tumors or the locally advanced disease is not
             amenable to local therapy, who have failed, or are intolerant to standard therapy or
             for whom no standard therapy is available. (For patients with hepatocellular
             carcinoma, the diagnosis needs to be supported by dynamic computed tomography
             [CT]/magnetic resonance imaging, if pathological confirmation is not attainable) and
             agree to provide fresh tumor tissues for genomic analysis.

          3. Harboring with below specific genetic alterations:

               1. NFE2L2 mutations

               2. STK11 mututions

               3. RICTOR amplifications

               4. Other genetic alterations maybe enrolled after discussion with Sponsor medical
                  monitor

          4. Eastern Cooperative Oncology Group (ECOG) performance status of < 2 at the screening.

          5. Able to comprehend and provide informed consent.

          6. A life expectancy longer than 3 months in the opinion of the Investigator.

          7. Adequate hematologic functions, as defined by: absolute neutrophil counts ≥ 1500/mm3;
             a hemoglobin level ≥ 9 g/dL; a platelet count ≥ 100,000/mm3.

          8. Adequate hepatic function defined by: a total bilirubin level ≤ 1.5 × of upper limit
             of normal (ULN); aspartate transaminase and alanine transaminase levels ≤ 2.5 ×
             ULN(AST and ALT ≤5 × ULN for subjects with liver metastasis).

          9. Adequate renal function, as defined by the creatinine clearance ≥ 50 mL/minute (as
             calculated by the Cockcroft-Gault formula).

         10. Females of child-bearing potential must have a negative pregnancy test upon entry into
             this study and must be willing to use highly effective birth control upon enrollment,
             during the Treatment Phase and for 180 days following the last dose of study drug. A
             female is considered of child-bearing potential following menarche and until becoming
             postmenopausal (no menstrual period for a minimum of 12 months) unless permanently
             sterile (undergone a hysterectomy, bilateral salpingectomy, or bilateral
             oophorectomy).

         11. If male, must be surgically sterile or willing to use highly effective birth control
             upon enrollment, during the Treatment Phase, and for 180 days following the last dose
             of study drug.

        Exclusion Criteria:

          1. Persistent ≥ Grade 2 toxicities from prior therapies, with the exception of alopecia
             of any grade, Grade ≤ 2 peripheral neuropathy, and laboratory values listed per the
             inclusion criteria.

          2. Concurrent unstable or uncontrolled medical conditions, including:

               1. Active systemic infections;

               2. Poorly controlled hypertension (systolic blood pressure ≥ 150 mmHg or diastolic
                  blood pressure ≥ 100 mmHg), or poor compliance with antihypertensive agents;

               3. Clinically significant arrhythmia, unstable angina pectoris, congestive heart
                  failure (Class II or IV of New York Heart Association) or acute myocardial
                  infarction;

               4. Uncontrolled diabetes or poor compliance with hypoglycemic agents (as defined:
                  HbA1c >7%);

               5. The presence of chronically unhealed wound or ulcers;

               6. Other chronic diseases, which, in the opinion of the Investigator, could
                  compromise safety of the patient or the integrity of the study.

          3. Any concurrent malignancy other than basal cell carcinoma or carcinoma in situ of the
             cervix. (Patients with a previous malignancy but without evidence of disease for ≥ 5
             years are allowed to participate).

          4. Females who are pregnant, lactating, or intend to become pregnant during their
             participation in this study.

          5. Known history of human immunodeficiency virus infection.

          6. Current or prior use of immunosuppressive medication within 14 days before the first
             dose. The following are exceptions to this criterion:

               1. Intranasal, inhaled, topical steroids or local steroid injections (eg,
                  intra-articular injection), OR

               2. systemic corticosteroids at physiologic doses not to exceed 10 mg/day of
                  prednisone or equivalent, OR

               3. steroids as premedication for hypersensitivity reactions (eg, CT scan
                  premedication).

          7. History of primary immunodeficiency or allogeneic transplantation.

          8. Active hepatitis B (HBsAg active),Active hepatitis C virus (HCV) infection, defined as
             having a positive HCV antibody test followed by a positive HCV RNA test at Screening.

          9. The patient is the Investigator, sub-investigator or anyone directly involved in the
             conduct of the study.